He had a complete recovery, but it was a long road filled with physical, occupational, and aqua therapy ... Guillain-Barre and its maker, Annexon Biosciences, hopes it will be another viable ...

The usual treatment approach neurologists take for Guillain-Barré Syndrome ... From the onset of GBS, physical therapy and ...

Guillain-Barré Syndrome is a rare condition that attacks a person's nerves. It can lead to muscle weakness and sometimes paralysis. When Rob was finally able to go home, his family turned part of ...

Annexon’s lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity ...

Featuring the striking image of a patient frozen in ice with the header “Guillain-Barré Syndrome ... the potential benefits from treatment with anti-C1q therapy; and continuing advancement ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment ... approved targeted therapy for GBS.

The company’s lead investigational therapy, tanruprubart ... the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ANX1502 in Cold Agglutinin ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes ... the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company’s ...

"After decades without any advancement in treatment or care, there is an urgent need for therapies that work quickly and effectively to treat GBS. Tanruprubart is an exciting and novel therapy ...